1.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng.
Am J Health Syst Pharm.
1997;54:692 - 693.
2.
Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors.
Mol Aspects Med.
1997;18(suppl):S137 - S144.
3.
Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study.
J Clin Pharmacol.
1993;33:226 - 229.
4.
Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphtoquinone analog of vitamin K and an inhibitor of coenzyme Q10- enzyme systems.
Res Commun Chem Pathol Pharmacol.
1976;13:109 - 114.
5.
Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter].
Lancet.
1994;344:1372 - 1373.
6.
Lo ACT, Chan K, Yeung JHK, et al. The effects of Danshen
(Salvia miltorrhiza)
on pharmacokinetics and pharmacodynamics of warfarin in rats.
Eur J Drug Metab Pharmacokinet.
1992;17:257 - 262.
7.
Brinker F.
Herb Contraindications and Drug Interactions: With Appendices Addressing Specific Conditions and Medicines.
2nd ed. Sandy, Ore: Eclectic Medical Publications; 1998.
8.
Chan TY. Interaction between warfarin and danshen
(Salvia miltiorrhiza).
Ann Pharmacother.
2001;35:501 - 504.
9.
Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements. A 5-year toxicological study (1991 - 1995).
Drug Saf.
1997;17:342 - 356.
10.
Page RL II, Lawrence JD. Potentiation of warfarin by dong quai.
Pharmacotherapy.
1999;19:870 - 876.
11.
Heptinstall S, Groenewegen WA, Spangenberg P, et al. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups.
J Pharm Pharmacol.
1987;39:459 - 465.
12.
Makheja AN, Bailey JM. The active principle in feverfew [letter].
Lancet.
1981;2:1054.
13.
Sumner H, Salan U, Knight DW, et al. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components.
Biochem Pharmacol.
1992;43:2313 - 2320.
14.
Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro.
J Pharm Pharmacol.
1990;42:553 - 557.
15.
Biggs MJ, Johnson ES, Persaud NP, et al. Platelet aggregation in patients using feverfew for migraine [letter].
Lancet.
1982;2:776.
16.
Gadkari JV, Joshi VD. Effect of ingestion of raw garlic on serum cholesterol level, clotting time and fibrinolytic activity in normal subjects.
J Postgrad Med.
1991;37:128 - 131.
17.
Burnham BE. Garlic as a possible risk for postoperative bleeding.
Plast Reconstr Surg.
1995;95:213.
18.
Kiesewetter H, Jung F, Jung EM, et al. Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischemic attack.
Eur J Clin Pharmacol.
1993;45:333 - 336.
19.
[No authors listed]. The effect of essential oil of garlic on hyperlipemia and platelet aggregation - an analysis of 308 cases. Cooperative Group for Essential Oil of Garlic.
J Tradit Chin Med.
1986;6:117 - 120.
20.
Bordia A. Effect of garlic on human platelet aggregation in vitro.
Atherosclerosis.
1978;30:355 - 360.
21.
Rose KD, Croissant PD, Parliament CF, et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report.
Neurosurgery.
1990;26:880 - 882.
22.
Sunter WH. Warfarin and garlic.
Pharm J.
1991;246:722.
23.
Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry.
Med Hypotheses.
1986;20:271 - 278.
24.
Srivastava KC. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism.
Biomed Biochim Acta.
1984;43:S335 - S346.
25.
Bordia A, Verma SK, Srivastava KC. Effect of ginger (
Zingiber officinale
Rosc.) and fenugreek (
Trigonella foenumgraecum
L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease.
Prostaglandins Leukot Essent Fatty Acids.
1997;56:379 - 384.
26.
Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger
(Zingiber officinale roscoe)
does not affect ex vivo platelet thromboxane production in humans.
Eur J Clin Nutr.
1996;50:772 - 774.
27.
Lumb AB. Effect of dried ginger on human platelet function.
Thromb Haemost.
1994;71:110 - 111.
28.
Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.
Lancet.
1987;1:248 - 251.
29.
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of
Ginkgo biloba
extract [letter].
N Engl J Med. 1997;336:1108.
30.
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas with chronic
Ginkgo biloba
ingestion.
Neurology.
1996;46:1775 - 1776.
31.
Vale S. Subarachnoid hemorrhage associated with
Ginkgo biloba
[letter].
Lancet.
1998;352:36.
32.
Matthews MK Jr. Association of
Ginkgo biloba
with intracerebral hemorrhage.
Neurology.
1998;50:1933 - 1934.
33.
Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea.
Ann Pharmacother.
1999;33:426 - 428.
34.
Monostory K, Vereczkey L, Levai F, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
Br J Pharmacol.
1998;123:605 - 610.
35.
Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements. A 5-year toxicological study (1991 - 1995).
Drug Saf.
1997;17:342 - 356.
36.
Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Int J Tissue React.
1998;20:119 - 124.
37.
Arruzazabala ML, Mas R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Int J Tissue React.
1998;20:119 - 124.
38.
Arruzazabala ML, Valdes S, Mas R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers.
Pharmacol Res.
1996;34:181 - 185.
39.
Arruzazabala ML, Valdes S, Mas R, et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers.
Pharmacol Res.
1997;36:293 - 297.
40.
Maurer A. Interaction of St. John's wort extract with phenprocoumon.
Eur J Clin Pharmacol.
1999;55:A22.
41.
Jobst KA, McIntyre M, St. George D, et al. Safety of St. John's wort
(Hypericum perforatum).
Lancet.
2000:355:575.
42.
Johne A, Brockmuller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort
(Hypericum perforatum).
Clin Pharmacol Ther.
1999;66:338 - 345.
43.
Yue QY, Bergquist C, Gerden B. Safety of St. John's wort [letter].
Lancet.
2000;355:576 - 577.
44.
Hitzenberger G, Sommer W, Grandt R. Influence of vinpocetine on warfarin-induced inhibition of coagulation.
Int J Clin Pharmacol Ther Toxicol.
1990;28:323 - 328.
45.
Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications.
J Am Dietet Assoc.
1995;95:580 - 584.
46.
Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications.
J Am Dietet Assoc.
1995;95:580 - 584.
47.
Schrogie JJ. Letter: Coagulopathy and fat-soluble vitamins.
JAMA.
1975;232:19.
48.
Rosenthal G. Interaction of ascorbic acid and warfarin [letter].
JAMA.
1971;215:1671.
49.
Smith EC, Skalski RJ, Johnson GC, et al. Interaction of ascorbic acid and warfarin [letter].
JAMA.
1972;221:1166.
50.
White JG, Rao GH, Gerrard JM. Effects of nitroblue tetrazolium and vitamin E on platelet ultrastructure, aggregation, and secretion.
Am J Pathol.
1977;88:387 - 402.
51.
Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin.
Am J Cardiol.
1996;77:545 - 546.
52.
Corrigan J, Marcus FI. Coagulopathy associated with vitamin E ingestion.
JAMA.
1974;230:1300 - 1301.
53.
Schrogie JJ. Letter: Coagulopathy and fat-soluble vitamins.
JAMA.
1975;232:19.
54.
Pedersen FM, Hamberg O, Hess K, et al. The effect of dietary vitamin K on warfarin-induced anticoagulation.
J Intern Med.
1991;229:517 - 520.
55.
Chow WH, Chow TC, Tse TM, et al. Anticoagulation instability with life-threatening complication after dietary modification.
Postgrad Med J.
1990;66:855 - 857.
56.
Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES [letter].
N Engl J Med.
2001;345:1213 - 1214.
57.
Lambert JP, Cormier A. Potential interaction between warfarin and boldo-fenugreek.
Pharmacotherapy.
2001;21:509 - 512.
58.
Su C, Shiao M, Wang C. Potentiation of ganodermic acid S on prostaglandin E(1)-induced cyclic AMP elevation in human platelets.
Thromb Res.
2000 Jul 15;99:135-145.
59.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and
Ginkgo biloba
on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.
Thromb Haemost.
2002;87:1075-1076.
60.
Kiss B, Karpati E. Mechanism of action of vinpocetine [in Hungarian; English abstract].
Acta Pharm Hung.
1996;66:213 - 214.
61. Sovak M, Seligson AL, Konas M, et al. PC-SPES in prostate cancer: an herbal mixture currently containing warfarin and previously diethylstilbestrol and indomethacin. Presented at: 93rd Annual Meeting of the American Association for Cancer Research; April 6-10, 2002; San Francisco, CA.
62.
AbdelFattah W, Hammad T. Chondroitin sulfate and glucosamine: A review of their safety profile.
JANA
2001;3:16-23.